DiaMedica Therapeutics Inc. - Common Stock — Quarterly Cash Flow (NASDAQ:DMAC) | MetaTrader

Open full chart

Financials

Overview Statement Statistics

Quarterly Annual

Total assets 38.83 M31.47 M57.05 M61.37 M53.08 M Total liabilities 4.88 M4.3 M5.42 M5.26 M5.84 M Total equity 33.95 M27.17 M51.62 M56.11 M47.23 M Total liabilities & shareholders' equities 38.83 M31.47 M57.05 M61.37 M53.08 M Total debt ————— Net debt —————

News

Top Wall Street Forecasters Revamp DiaMedica Therapeutics Expectations Ahead Of Q4 Earnings - DiaMedica Therapeutics (NASDAQ:DMAC)

DiaMedica receives Health Canada clearance for preeclampsia study

Cantor Fitzgerald reiterates Overweight rating on DiaMedica stock

DiaMedica to conduct additional study for preeclampsia treatment

Cisco, Flutter, Manulife and more set to report earnings Wednesday

DiaMedica Therapeutics stock initiated with Buy rating at TD Cowen

Tracking Leon Cooperman’s ~$3B Omega Advisors Portfolio – Q2 2025 Update

DiaMedica Therapeutics, Inc. (DMAC) is a Great Momentum Stock: Should You Buy?

After Golden Cross, DiaMedica Therapeutics, Inc. (DMAC)'s Technical Outlook is Bright

Wall Street Analysts Believe DiaMedica Therapeutics (DMAC) Could Rally 100.81%: Here's is How to Trade

What Makes DiaMedica Therapeutics, Inc. (DMAC) a Strong Momentum Stock: Buy Now?

Does DiaMedica Therapeutics (DMAC) Have the Potential to Rally 114.06% as Wall Street Analysts Expect?